Corpus overview


MeSH Disease

Human Phenotype

Cough (20)

Fever (17)

Anosmia (5)

Fatigue (5)

Pneumonia (4)


    displaying 1 - 10 records in total 20
    records per page

    Estimates of the rate of infection and asymptomatic MESHD asymptomatic TRANS COVID-19 disease MESHD in a population sample from SE England

    Authors: Philippa M Wells; Katie M Doores; Simon Couvreur; Rocio Martin Martinez; Jeffrey Seow; Carl Graham; Sam Acors; Neophytos Kouphou; Stuart Neil; Richard Tedder; Pedro Matos; Kate Poulton; Maria Jose Lista; Ruth Dickenson; Helin Sertkaya; Thomas Maguire; Edward Scourfield; Ruth Bowyer; Deborah Hart; Aoife O'Byrne; Kathryn Steele; Oliver Hemmings; Carolina Rosadas; Myra McClure; Joan Capedevila-Pujol; Jonathan wolf; Sebastien Ourseilin; Matthew Brown; Michael Malim; Timothy Spector; Claire Steves

    doi:10.1101/2020.07.29.20162701 Date: 2020-07-30 Source: medRxiv

    Background: Understanding of the true asymptomatic TRANS rate of infection MESHD of SARS-CoV-2 is currently limited, as is understanding of the population-based seroprevalence SERO after the first wave of COVID-19 within the UK. The majority of data thus far come from hospitalised patients, with little focus on general population cases, or their symptoms. Methods: We undertook enzyme linked immunosorbent assay SERO characterisation of IgM and IgG responses against SARS-CoV-2 spike glycoprotein and nucleocapsid protein of 431 unselected general-population participants of the TwinsUK cohort from South-East England, aged TRANS 19-86 (median age TRANS 48; 85% female TRANS). 382 participants completed prospective logging of 14 COVID-19 related symptoms via the COVID Symptom Study App, allowing consideration of serology alongside individual symptoms, and a predictive algorithm for estimated COVID-19 previously modelled on PCR positive individuals from a dataset of over 2 million. Findings: We demonstrated a seroprevalence SERO of 12% (51participants of 431). Of 48 seropositive individuals with full symptom data, nine (19%) were fully asymptomatic TRANS, and 16 (27%) were asymptomatic TRANS for core COVID-19 symptoms: fever MESHD fever HP, cough MESHD cough HP or anosmia HP. Specificity of anosmia HP for seropositivity was 95%, compared to 88% for fever MESHD fever HP cough MESHD cough HP and anosmia HP combined. 34 individuals in the cohort were predicted to be Covid-19 positive using the App algorithm, and of those, 18 (52%) were seropositive. Interpretation: Seroprevalence SERO amongst adults TRANS from London and South-East England was 12%, and 19% of seropositive individuals with prospective symptom logging were fully asymptomatic TRANS throughout the study. Anosmia HP demonstrated the highest symptom specificity for SARS-CoV-2 antibody SERO response. Funding: NIHR BRC, CDRF, ZOE global LTD, RST-UKRI/MRC

    The SARS-CoV-2 RNA with mild lung lesions lasts longer in non-severe COVID-19 patients: a case series study

    Authors: Chi Zhang; Jiawen Li; Jing Mu; Daitao Zhang; He Wang; Yunv Jin; Yan Han; Haiyang Li; Chunxiao Zhang; Peng Yu; Rui Guo; Xiangfeng Dou; Yanhui Chu; Zhao Wu; Xiaoqin Dong; Hong Zhao

    doi:10.21203/ Date: 2020-07-15 Source: ResearchSquare

    Background COVID-19 has become a new infectious disease MESHD in the global pandemic, most of which are non-severe patients. It is particularly important to understand the dynamic changes of the whole disease MESHD course of non-severe patients from the onset to the follow-up after discharge.Methods On February 1, 2020, 18 cases of non-severe COVID-19 appeared in a hospital in Beijing. We recorded the clinical information and viral dynamics of these patients from the onset of the disease MESHD to one month after discharge.Results Eighteen patients (median age TRANS 43) were included, including 14 females TRANS. Fever MESHD Fever HP (11/18) and cough MESHD cough HP (8/18) are the most common symptoms. According to the degree of lung inflammation MESHD, 18 patients were divided into two groups (group A imaging score ≤ 10; group B imaging score > 10). The duration of SARS-CoV-2 positive in group A was significantly longer than that in group B (the median was 30 and 13, respectively, P = 0.0025). One month after discharge, almost all patients were followed up for IgM antibody SERO disappearance and IgG antibody SERO production.Conclusion In non-severe COVID-19 patients, the positive duration of the SARS-CoV-2 in patients with mild lung injury MESHD was longer than that in patients with severe lung injury MESHD. The possible mechanism is that the virus-mediated immune system is not fully activated in mild damaged patients.

    Placental SARS-CoV-2 in a patient with mild COVID-19 disease MESHD

    Authors: Albert L. Hsu; Minhui Guan; Eric Johannesen; Amanda J. Stephens; Nabila Khaleel; Nikki Kagan; Breanna C. Tuhlei; Xiu-Feng Wan

    doi:10.1101/2020.07.11.20149344 Date: 2020-07-14 Source: medRxiv

    Background: The full impact of COVID-19 on pregnancy remains uncharacterized. Current literature suggests minimal maternal, fetal, and neonatal morbidity and mortality,1 and COVID-19 manifestations appear similar between pregnant and non-pregnant women.2 We present a case of placental SARS-CoV-2 virus in a woman with an uncomplicated pregnancy and mild COVID-19 disease MESHD. Methods: A pregnant woman was evaluated at University of Missouri Women and Childrens Hospital. Institutional review board approval was obtained; information was obtained from medical records. Reverse transcriptase-polymerase chain reaction (RT-PCR) was performed to detect SARS-CoV-2. A gynecological pathologist examined the placenta and performed histolopathology. Sections were formalin-fixed and paraffin-embedded; slides were cut and subjected to hematoxylin-and-eosin or immunohistochemistry (IHC) staining. IHC was performed with specific monoclonal antibodies SERO to detect SARS-CoV-2 antigen or to identify trophoblasts. Findings: A 29 year-old multigravida presented at 40-4/7 weeks for labor induction. With myalgias MESHD myalgias HP two days prior, she tested positive for SARS-CoV-2. Her parents TRANS were in self-isolation for COVID-19 positivity; husband was asymptomatic TRANS and tested negative for COVID-19, but exposed to a workplace (meatpacking facility) outbreak. Prenatal course was uncomplicated, with no gestational hypertension MESHD hypertension HP. She was afebrile and asymptomatic TRANS with normal vital signs throughout hospitalization. Her myalgias MESHD myalgias HP improved prior to admission. A liveborn male TRANS infant was delivered vaginally. Newborn course was uneventful; he was appropriate for gestational age TRANS, physical was unremarkable, and he was discharged home at 36 hours. COVID-19 RT-PCR test was negative at 24 hours. At one-week follow-up, newborn was breastfeeding well, with no fevers MESHD fevers HP or respiratory distress HP. Overall placental histology is consistent with acute uterine hypoxia MESHD (subchorionic laminar necrosis MESHD) superimposed on chronic uterine hypoxia MESHD (extra-villous trophoblasts and focal chronic villitis). IHC using SARS-CoV-2 nucleocapsid-specific monoclonal antibody SERO demonstrated SARS-CoV-2 antigens throughout the placenta in chorionic villi endothelial cells, and rarely in CK7-expressing trophoblasts. Negative control placenta (November 2019 delivery) and ferret nasal turbinate tissues (not shown) were negative for SARS-CoV-2. Interpretation: In this report, SARS-CoV-2 was found in the placenta, but newborn was COVID-19 negative. Our case shows maternal vascular malperfusion, with no features of fetal vascular malperfusion. To our knowledge, this is the first report of placental COVID-19 despite mild COVID-19 disease MESHD in pregnancy (with no symptoms of COVID-19 aside from myalgias MESHD myalgias HP); specifically, this patient had no fever MESHD fever HP, cough MESHD cough HP, or shortness of breath, but only myalgias MESHD myalgias HP and sick contacts. Despite her having mild COVID-19 disease MESHD in pregnancy, we demonstrate placental vasculopathy and presence of SARS-CoV-2 virus across the placenta. Evidence of placental COVID-19 raises concern for possible placental vasculopathy (potentially leading to fetal growth restriction, pre-eclampsia MESHD eclampsia HP, and other pregnancy complications MESHD) as well as for potential vertical transmission TRANS -- especially for pregnant women who may be exposed to COVID-19 in early pregnancy. Further studies are urgently needed, to determine whether women with mild, pre-symptomatic, or asymptomatic TRANS COVID-19 may have SARS-CoV-2 virus that can cross the placenta, cause fetal vascular malperfusion, and possibly affect the fetus. This raises important public health and public policy questions of whether future pregnancy guidance should include stricter pandemic precautions, such as screening for a wider array of COVID-19 symptoms, increased antenatal surveillance, and possibly routine COVID-19 testing on a regular basis throughout pregnancy.

    Epidemiological and Clinical Features of Imported and Local Patients with Coronavirus Disease MESHD 2019 (COVID-19) in Hainan, China

    Authors: Biao Wu; Zi-Ying Lei; Kun-Liang Wu; Jian-Rong He; Hui-Juan Cao; Juan Fu; Feng Chen; Yuan Chen; Bao Chen; Xiao-Li Zhou; Tao Huang; Tao Wu; Yong-Guo Du; Suo-Xian Chen; Fu-Rong Xiao; Zhi-Liang Gao; Jing He; Feng Lin; Bingliang Lin

    doi:10.21203/ Date: 2020-07-01 Source: ResearchSquare

    Background: Hainan Island, a popular tourist destination, had received many imported cases of Coronavirus disease MESHD 2019 (COVID-19), but successfully contained the epidemics in one month. We described epidemiological and clinical characteristics of COVID-19 in Hainan and compared these features between imported and local cases to provide information for other international epidemic areas.Methods: We included 91 patients (56 imported and 35 local cases) from two designed hospitals for COVID-19 in Haikou, China, from January 20 to February 19, 2020. Data on demographic, epidemiological, clinical and laboratory characteristics were extracted from medical records. Patients were followed up until April 21, 2020, the levels of antibodies SERO in the follow-up were also analyzed.Results: Of the 91 patients, 78 (85.7%) patients were diagnosed within the first three weeks after the first case identified (Day 1: Jan 22, 2020), while the number of local cases started to increase from the third week. No new cases occurred after Day 29. Fever MESHD Fever HP and cough MESHD cough HP were two main clinical manifestations. 15 (16.5%) were severe, 14 (15.4%) had complicated infections MESHD, nine (9.9%) were admitted to ICU, and three died. Median duration of viral shedding in feces was longer than that in nasopharyngeal swabs (19 days vs 16 days, P=0.007). Compared with local cases, imported cases were older, have higher incidence of fever MESHD fever HP and concurrent infections MESHD. There was no difference in outcomes between the two groups. IgG was positive in 92.8% patients (77/83) in the follow-up of week 2 after discharge, 88.4% patients (38/43) had a reduction in IgG levels in the follow-up of week 4 after discharge, and the median level was lower than that in the follow-up of week 2 (10.95 S/CO vs 15.02 S/CO, P<0.001)Conclusion: Imported cases were more severe than local cases, but could have similar prognosis. The level of IgG antibodies SERO declined from week 6 to week 8 after onset. The short epidemic period in Hainan suggests that the epidemics could be quickly brought under control if proper timely measures were taken. 

    Clinical Characteristics of COVID-19 Patients with Recurrent PCR Positivity After Hospital Discharge

    Authors: Kaige Wang; Qifan Zhang; Dong Lan; Yalun Li; Wenxin Luo; Shengmin Zhao; Dan Liu; Tian Panwen; Zhixin Huang; Weimin Li

    doi:10.21203/ Date: 2020-06-26 Source: ResearchSquare

    Objective: This study aimed to investigate the clinical characteristics of COVID-19 patients with recurrent SARS-CoV-2 positivity after hospital discharge. Methods: This retrospective study included COVID-19 patients who were readmitted for recurrence MESHD of positive SARS-CoV-2 RNA. Univariate and multivariate analyses were performed to assess the risk factors associated to the duration of recurrent RNA positivity.Results: Among the 287 discharged COVID-19 patients, 33 (11.5%) patients with recurrent PCR positivity were included. Among these patients, 21 (63.7%) patients were female TRANS, their mean age TRANS was 48.7 (±19.7) years old. 22 (66.7%) patients were asymptomatic TRANS. The following clinical features were presented in other patients: cough MESHD cough HP, fatigue MESHD fatigue HP, sore throat, fever MESHD fever HP and expectoration. The chest CT findings revealed that 8 (24.2%) patients were characterized by deterioration compared to the previous results. The median duration of recurrent RNA positivity was 9.0 days (IQR, 6.0, 15.0). We found that increased serum SERO SARS-CoV-2-specific IgG antibody SERO titer, elevated serum creatinine HP serum SERO creatinine level, and female TRANS gender TRANS were the risk factors for the prolonged duration of recurrent RNA positivity.Conclusion: SARS-CoV-2 turned positive in a minority of discharged patients with COVID-19. Most patients experienced mild clinical course. Increased IgG antibody SERO titer, creatinine and female TRANS gender TRANS were correlated to the prolonged RNA clearance time.

    A cross-sectional study of immune seroconversion to SARS-CoV-2 in front-line maternity health professionals

    Authors: Sohail Bampoe; Dominique Nuala Lucas; Georgina Neall; Penny Sceales; Reena Aggarwal; Dimitrios Siassakos; Peter Mark Odor

    doi:10.1101/2020.06.24.20139352 Date: 2020-06-26 Source: medRxiv

    COVID-19, the respiratory disease MESHD caused by the SARS-CoV-2, is thought to cause a milder illness in pregnancy with a greater proportion of asymptomatic TRANS carriers TRANS. This has important implications for the risk of patient-to-staff, staff-to-staff and staff-to patient transmission TRANS among health professionals in maternity. The aim of this study was to investigate the prevalence SERO of previously undiagnosed SARS-CoV-2 infection MESHD in health professionals from two tertiary-level maternity units in London, UK and to determine associations between HCW characteristics, reported symptoms and serological evidence of prior SARS-CoV-2 infection MESHD. 200 anaesthetists, midwives and obstetricians with no previously confirmed diagnosis of COVID-19 were tested for immune seroconversion using laboratory IgG assays. Comprehensive symptom and medical histories were also collected. 5/40 (12.5%; 95% CI: 4.2-26.8) anaesthetists, 7/52 (13.5%; 95% CI: 5.6-25.8%) obstetricians and 17/108 (15.7%; 95% CI: 9.5-24.0%) midwives were seropositive, with an overall total of 29/200 (14.5%; 95% CI: 9.9-20.1%) of maternity healthcare workers testing positive for IgG antibodies SERO against SARS-CoV-2. Of those who had seroconverted, 10/29 (35.5%) were completely asymptomatic TRANS. Fever MESHD Fever HP or cough MESHD cough HP were only present in 6/29 (20.7%) and (10/29 (34.5%) respectively. Anosmia HP was the most common symptom occurring in 15/29 (51.7%) seropositive participants and was the only symptom that was predictive of positive seroconversion (OR 18; 95% CI 6 to 55). 58.6% of those who were seropositive had not self-isolated at any point and continued to provide patient care in the hospital setting. This study was the largest study of baseline immune seroconversion in maternity healthcare workers conducted to date and reveals that 1 in 6 were seropositive, of whom 1 in 3 were asymptomatic TRANS. This has significant implications for the risk of occupational transmission TRANS of SARS-CoV-2 for both staff and patients in maternity and regular testing of staff, including asymptomatic TRANS staff should be considered to reduce transmission risk TRANS.

    A population-based study of the prevalence SERO of COVID-19 infection MESHD in Espirito Santo, Brazil: methodology and results of the first stage

    Authors: Cristiana Costa Gomes; Crispim Cerutti Jr.; Eliana Zandonade; Ethel Leonor Noia Maciel; Filomena Euridice Carvalho de Alencar; Gilton Luiz Almada; Orlei Amaral Cardoso; Pablo Medeiros Jabor; Raphael Lubiana Zanotti; Tania Queiroz Reuter; Vera Lucia Gomes de Andrade; Whisllay Maciel Bastos; Nesio Fernandes de Medeiros Jr.

    doi:10.1101/2020.06.13.20130559 Date: 2020-06-16 Source: medRxiv

    BACKGROUND: COVID-19 is affecting almost the entire world, causing more than four hundred thousand deaths MESHD and undermining the health care systems, as much as the economy, of the afflicted countries. The strategies for prevention depend on largely lacking information, as infection MESHD prevalence SERO and virus pathogenicity. This study aimed to determine the prevalence SERO, the pathogenicity, and the speed of infection MESHD spreading in a large population in Brazil. MATERIALS AND METHODS: This is a serial cross-sectional study designed on a population basis and structured over houses as the sampling units. The sampling consisted of four visits at 15 days intervals in randomly selected census-designated sectors of the State major municipalities (reference municipalities) and two visits at 30 days intervals in smaller municipalities of the same regions of those of reference. At each visit, the investigators sampled houses and sampled one individual in each house for data collection. After the informed consent, the investigators performed a rapid antibody SERO detection test (Celer Technology, Inc) and applied a questionnaire containing clinical and demographic questions. RESULTS: From May 13th to 15th, the investigators performed 6,393 rapid tests SERO in 4,612 individuals of the reference municipalities, 1,163 individuals of the smaller municipalities, and 166 contacts of the positive individuals. Ninety-seven dwellers were positive in the reference municipalities, giving a prevalence SERO of 2.1% (CI 95%: 1.67-2.52%). In the smaller municipalities, the figure was 0.26% (CI 95%: 0.05%-0.75%) (three positives). There was an association of the positive result with female TRANS sex (p = 0.013) and houses with five dwellers or more (p = 0.003). Seventy-eight positive individuals reported symptoms in the previous 15 days (80.4%), being anosmia HP (45.4%), cough MESHD cough HP (40.2%), and myalgia MESHD myalgia HP (38.1%) the more frequent. About one-third of them reported fever MESHD fever HP (28.9%). CONCLUSIONS: The results reveal a still small prevalence SERO of infection MESHD in the study area, despite the significant number of sick people overloading the health system. The figures indicate an important underreporting in the area and a frequency that still can grow, making necessary public health actions for the containment of the transmission TRANS.

    SARS-CoV-2 Serology Results in the First COVID-19 Case in California: A Case Report and Recommendations for Serology Testing and Interpretation

    Authors: Richard B. Lanman, MD; Todd H. Lanman

    doi:10.21203/ Date: 2020-06-12 Source: ResearchSquare

    Background: As countries in COVID-19 pandemic lockdown begin relaxation of shelter-in-place mitigation strategies, the role of serology testing escalates in importance. However, there are no clear guidelines as to when to use qualitative rapid diagnostic serology tests (RDTs) vs. SARS-CoV-2 viral RNA load (PCR) tests as an aid in acute diagnosis of patients presenting with flu-like symptoms, nor how to interpret serology test results in asymptomatic TRANS individuals or those with atypical COVID-19 symptomatology. Here we describe, in the context of the likely first case of COVID-19 in California, with an atypical presentation and not tested acutely, who nearly 3 months later was found to be IgM- and IgG+ positive for SARS-CoV-2 antibodies SERO, highlighting the role of RDT- based serology testing SERO and interpretation in retrospective diagnosis.Case Presentation: A 62-year-old male TRANS practicing neurosurgeon had onset of flu-like symptoms on January 20 with fatigue MESHD fatigue HP, slight cough MESHD cough HP only on deep inspiration, intermittent pleuritic chest pain MESHD chest pain HP unrelated to exertion, dyspnea MESHD dyspnea HP, and night sweats HP but without fever MESHD fever HP, sore throat or rhinorrhea HP. He had recently traveled TRANS abroad but not to China. CT scan revealed right lower lobe infiltrate and effusion. Because of atypical symptoms, and low prevalence SERO of COVID-19 in January, community acquired pneumonia MESHD pneumonia HP was diagnosed and one week of doxycycline was prescribed without relief, followed by a second week of azithromycin with symptom remission. Three months later the physician-patient (author THL), tested positive for SARS-CoV-2 antibodies SERO by a serology point-of-care rapid diagnostic test (RDT).Conclusions: Serology testing may be an aid in acute diagnosis of COVID-19, especially in patients with atypical presentations, as well as in assessment of asymptomatic TRANS higher-risk persons such as healthcare workers for prior infection MESHD. Recommendations for serology testing and interpretation are explicated.

    COVID-19 relapse with prolonged viral shedding up to 60 days or re- infection MESHD, in 3 frontline healthcare workers with recurrent symptoms and persistent SARS-CoV-2 PCR positivity in Ireland, a developing diagnostic challenge: A case report

    Authors: Jonathan McGrath; Tara McGinty; Maureen Lynch; Edel O'Regan; Dominic Natin; Peter O'Gorman; John S Lambert

    doi:10.21203/ Date: 2020-06-09 Source: ResearchSquare

    Background:To date, the Corona Virus Disease MESHD-2019 (COVID-19) pandemic has resulted in more than 24,400 confirmed cases TRANS in Ireland, with more than 30% involving Healthcare Workers (HCW). As more staff become involved in the care of COVID-19 patients, many key clinical considerations remain uncertain, including the possibility of re- infection MESHD following initial illness, the clinical significance of prolonged viral shedding and the degree of protection conferred by development of anti- Severe Acute Respiratory Syndrome MESHD Coronavirus 2 ( SARS-CoV-2) antibodies SERO.We present 3 cases of COVID19-infected HCWs, each with distinct episodes of recurrent symptoms following initial resolution and with persistently positive SARS-CoV-2 PCR results, ranging up to 60 days post onset of illness. PCR results, cycle threshold (Ct) values and clinical assessment are provided to discuss the diagnostic difficulties in assessing relapsed COVID-19 infection MESHD, or re- infection MESHD with new virus following return to work. Case presentations: Patient 1,2 and 3 ( age TRANS range 25-36) tested positive for SARS-CoV-2 via rtPCR on oro/nasopharyngeal swab with initial Ct values of 21.72, 24.52 and 26.58 respectively, following presentation with respiratory symptoms. All completed 14 day periods of self-isolation with full resolution of symptoms. Each patient has a clinical role and was involved in the management of COVID-19 patients following return to work. Patient 1 was admitted to hospital 44 days after initial illness, with cough MESHD cough HP, dyspnoea and a concurrent diagnosis of neurosyphilis MESHD. SARS-CoV-2 PCR was positive with Ct value 31.36 and remained positive for at least 60 days following initial illness onset. A full clinical recovery followed. Patients 2 and 3 represented to the Emergency MESHD Department with recurrent respiratory symptoms 29 and 40 days following initial illness onset respectively. SARS-CoV-2 PCR was demonstrated in each with Ct values 31.16 and 30.72 respectively. Each subsequently made a full recovery following a second period of self-isolation. Anti-SARS-CoV-2 IgG was demonstrated in all 3 patients. Conclusions: These cases demonstrate the diagnostic difficulties in determining intermittent presentation of COVID-19 infection MESHD with prolonged viral shedding, or re- infection MESHD with new virus following return to work.  As the pandemic progresses, this represents a growing diagnostic challenge impacting patient assessment, staff deployment following illness and infection MESHD control. 

    Covid-19 in the second half of pregnancy: prevalence SERO and clinical relevance

    Authors: Marta RUGGIERO; Edgardo SOMIGLIANA; Beatrice TASSIS; Letizia LI PIANI; Sara UCEDA RENTERIA; Giussy BARBARA; Giovanna LUNGHI; Enrico FERRAZZI

    doi:10.21203/ Date: 2020-06-09 Source: ResearchSquare

    Evidence on the prevalence SERO and outcome of Covid-19 in pregnancy is yet inconclusive. To draw more information on this issue, we prospectively recruited 315 consecutive women delivering in a referral hospital located in Lombardy, Italy and evaluated the proportion of women who had Covid-19 in pregnancy. All recruited subjects underwent a nasopharyngeal swab to assess the presence of Sars-Cov-2 using Real-time PCR. In addition, two different type of antibodies SERO for the virus were evaluated in peripheral blood SERO, those against the spike proteins S1 and S2 of the envelope and those against the nucleoprotein of the nucleocapsid. Women were considered to have had Covid-19 in pregnancy if at least one of the assessment was positive. Overall, 28 women had a diagnosis of Covid-19 in pregnancy (8.9%, 95%CI: 6.2-12.5%), in line with the local general population. Women diagnosed with the infection MESHD were more likely to report one or more episodes of symptoms suggestive for Covid-19 (n=11, 39.3%) compared to unaffected women (n=39, 13.6%). The corresponding OR was 4.11 (95%CI: 1.79-9.44). Symptoms significantly associated with Covid-19 in pregnancy included fever MESHD fever HP, cough MESHD cough HP, dyspnea MESHD dyspnea HP and anosmia HP. Only one woman necessitated intensive care. No maternal deaths MESHD occurred. Pregnancy outcome in women with and without Covid-19 did not also differ. In conclusion, women in the second half of pregnancy do not appear to be more susceptible to Covid-19 and its complications. In addition, the study suggests that pregnancy outcome may not be significantly affected.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.